Valuation Novo Nordisk A/S

Equities

Real-time Estimate Cboe Europe Other stock markets 04:35:12 2025-01-21 am EST			5-day change	1st Jan Change
565.45 ^DKK	+2.57%		-5.22%	-10.06%

Jan. 03	New Year, Soft Start
Jan. 03	BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	909,347	986,612	1,674,992	2,118,803	3,112,331	2,448,137	2,448,137	-
Change	-	8.5%	69.77%	26.5%	46.89%	-21.34%	0%	-
Enterprise Value (EV) ¹	898,355	984,211	1,684,152	2,121,013	3,109,107	2,508,403	2,474,726	2,450,546
Change	-	9.56%	71.12%	25.94%	46.59%	-19.32%	-1.34%	-0.98%
P/E ratio	23.6x	23.7x	35.4x	38.4x	37.5x	24.7x	20.1x	16.6x
PBR	15.8x	15.8x	24x	25.6x	29.4x	17.4x	11.9x	9.48x
PEG	-	2.38x	2.3x	2.2x	0.7x	1.2x	0.9x	0.8x
Capitalization / Revenue	7.45x	7.77x	11.9x	12x	13.4x	8.55x	7.05x	6.01x
EV / Revenue	7.36x	7.75x	12x	12x	13.4x	8.76x	7.13x	6.01x
EV / EBITDA	15.5x	16.4x	26x	25.8x	27.8x	17.7x	14.3x	11.9x
EV / EBIT	17.1x	18.2x	28.7x	28.4x	30.3x	19.9x	15.7x	13.1x
EV / FCF	26.1x	34.5x	57.4x	37x	45.5x	35.6x	26.7x	20.3x
FCF Yield	3.83%	2.9%	1.74%	2.7%	2.2%	2.81%	3.74%	4.93%
Dividend per Share ²	4.175	4.55	5.2	6.2	9.4	10.93	13.94	16.95
Rate of return	2.16%	2.13%	1.41%	1.32%	1.35%	1.98%	2.53%	3.07%
EPS ²	8.19	9.005	10.37	12.22	18.62	22.36	27.49	33.23
Distribution rate	51%	50.5%	50.1%	50.7%	50.5%	48.9%	50.7%	51%
Net sales ¹	122,021	126,946	140,800	176,954	232,261	286,196	347,259	407,471
EBITDA ¹	58,144	59,879	64,669	82,171	111,987	141,904	173,060	206,640
EBIT ¹	52,483	54,126	58,644	74,809	102,574	126,110	157,183	186,570
Net income ¹	38,951	42,138	47,757	55,525	83,683	100,585	123,602	147,515
Net Debt ¹	-10,992	-2,401	9,160	2,210	-3,224	60,266	26,589	2,409
Reference price ²	193.32	213.32	367.50	469.00	698.10	551.30	551.30	551.30
Nbr of stocks (in thousands)	4,703,720	4,624,923	4,557,801	4,517,704	4,458,288	4,440,662	4,440,662	-
Announcement Date	2/5/20	2/3/21	2/2/22	2/1/23	1/31/24	-	-	-

¹DKK in Million²DKK

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield	Capi. ($)
NOVO NORDISK A/S	24.65x	8.76x	17.68x	+1.98%	341B
ELI LILLY AND COMPANY	57.77x	14.92x	41.72x	+0.72%	653B
JOHNSON & JOHNSON	21.23x	4.11x	12x	+3.24%	354B
ABBVIE INC.	38.39x	6.45x	14.22x	+3.63%	303B
MERCK & CO., INC.	13.9x	4.23x	10.08x	+3.11%	248B
ROCHE HOLDING AG	16.1x	3.79x	9.91x	+3.69%	236B
ASTRAZENECA PLC	24.9x	4.29x	13.43x	+2.34%	206B
NOVARTIS AG	17.77x	4.18x	10.65x	+3.84%	197B
PFIZER, INC.	14.97x	3.29x	8.35x	+6.34%	149B
AMGEN INC.	29.79x	5.9x	10.38x	+3.32%	146B
Average	25.95x	5.99x	14.84x	+3.22%	283.38B
Weighted average by Cap.	30.97x	7.46x	19.17x	+2.72%